Interestingly, and connected to the role of PARP14 in IFN-mediated signalling, tumours with an acquired resistance to immune checkpoint blockade therapy (such as immunotherapy targeting programmed cell death protein 1, referred as α-PD-1 therapy) show increased PARP14 mRNA levels, along with IFNγ genes. Here, PARP14 is linked to neoplasm.